Health care pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 health care pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8). Figures as of 20 Nov 2026, 00:32 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- AED 18.23T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | AED 16.6B | AED 151.21 | 0.48% down | 86% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | AED 72.7B | AED 542.91 | 1.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 9.8 | AED 629.2B | AED 142.76 | 1.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 9.9 | AED 20.5B | AED 30.12 | 3.19% down | 0% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 12.9 | AED 438B | AED 214.27 | 2.05% down | 30% up | ||
| 6 | ZoetisZTS · Health Care | 13.7 | AED 120.6B | AED 296.73 | 5.59% down | 26% down | ||
| 7 | GSKGSK · Health Care | 16.7 | AED 352.1B | AED 175.63 | 1.56% down | 5% up | ||
| 8 | Ascendis PharmaASND · Health Care | 16.8 | AED 61.7B | AED 940.09 | 5.32% down | 29% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | AED 350.8B | AED 3,391.24 | 2.35% down | 28% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.1 | AED 87.5B | AED 2,053.46 | 3.16% down | 22% up | ||
| 11 | SanofiSNY · Health Care | 22.9 | AED 406.2B | AED 169.17 | 2.25% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 24.8 | AED 999.2B | AED 644.25 | 1.87% down | 1% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.2 | AED 29.7B | AED 455.50 | 2.47% down | 51% up | ||
| 14 | NovartisNVS · Health Care | 28.9 | AED 1.05T | AED 555.40 | 2.57% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | AED 484.8B | AED 1,912.28 | 2.94% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.8 | AED 660.7B | AED 381.49 | 0.58% down | 16% down | ||
| 17 | PfizerPFE · Health Care | 39.3 | AED 576.5B | AED 101.15 | 1.85% down | 15% up | ||
| 18 | Johnson & JohnsonJNJ · Health Care | 40.5 | AED 2.36T | AED 981.15 | 2.04% down | 34% up | ||
| 19 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.2 | AED 45.4B | AED 54.47 | 1.00% down | 8% up | ||
| 20 | Eli LillyLLY · Health Care | 43.9 | AED 4.42T | AED 4,962.39 | 2.29% down | 33% up | ||
| 21 | GenmabGMAB · Health Care | 43.9 | AED 116.3B | AED 188.60 | 0.75% up | 70% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 44.3 | AED 143B | AED 248.72 | 1.38% down | 79% up | ||
| 23 | AbbVieABBV · Health Care | 48.7 | AED 1.84T | AED 1,041.39 | 0.86% down | 25% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 48.9 | AED 26.1B | AED 238.66 | 4.15% down | 10% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.2 | AED 167.7B | AED 1,468.02 | 0.97% down | 16% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.5 | AED 27.4B | AED 78.56 | 2.24% down | 90% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 70.0 | AED 55.7B | AED 868.43 | 4.57% down | 41% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 70.9 | AED 27B | AED 343.54 | 1.59% down | 129% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 89.6 | AED 165.2B | AED 141.55 | 8.74% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 96.8 | AED 36B | AED 238.29 | 1.88% down | 117% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 115 | AED 21.1B | AED 1,053.87 | 3.94% down | 50% up | ||
| 32 | Merck & CoMRK · Health Care | 134 | AED 1.2T | AED 487.78 | 3.61% down | 45% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | AED 251.2B | AED 78.63 | 0.66% up | 51% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8) have the lowest P/E ratio of the 33 health care pharmaceutical companies ranked here as of 20 Nov 2026, 00:32 UTC.
How many health care pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 33 health care pharmaceutical companies ranked by P/E ratio have a combined market value of AED 18.23T as of 20 Nov 2026, 00:32 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/E ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.